Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Assets (2018 - 2026)

Bicycle Therapeutics (BCYC) has disclosed Non-Current Assets for 9 consecutive years, with $20.3 million as the latest value for Q1 2026.

  • For Q1 2026, Non-Current Assets rose 31.21% year-over-year to $20.3 million; the TTM value through Mar 2026 reached $20.3 million, up 31.21%, while the annual FY2025 figure was $21.9 million, 27.45% up from the prior year.
  • Non-Current Assets hit $20.3 million in Q1 2026 for Bicycle Therapeutics, down from $21.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $37.0 million in Q1 2023 and bottomed at $11.4 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $24.5 million, with a median of $24.8 million recorded in 2024.
  • Year-over-year, Non-Current Assets skyrocketed 442.27% in 2022 and then crashed 44.58% in 2025.
  • Bicycle Therapeutics' Non-Current Assets stood at $32.8 million in 2022, then fell by 15.52% to $27.7 million in 2023, then tumbled by 37.91% to $17.2 million in 2024, then grew by 27.45% to $21.9 million in 2025, then dropped by 7.48% to $20.3 million in 2026.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $20.3 million, $21.9 million, and $11.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.